Table 1.
Clinicopathological Characteristics of Study Subjects
| Characteristic | Subjects (n = 28) | P-value | |
|---|---|---|---|
| F-18 Fluciclovine–Positive (n = 17) | F-18 Fluciclovine–Negative (n = 11) | ||
| Age at prostatectomy, years (Mean ± SD) | 66 ± 6 | 61 ± 8 | .11 |
| Prior cancer therapies (N) | 1.00 | ||
| Prostatectomy only | 17 | 11 | |
| Prostatectomy + Radiation therapy | 4/17 (24%) | 2/11 (18%) | |
| Initial Gleason score (N) | .22b | ||
| No records or missing | 2 (12%) | 2 (18%) | |
| 6 | 1 (6%) | 0 (0%) | |
| 7 | 9 (53%) | 7 (64%) | |
| 8 | 4 (24%) | 2 (18%) | |
| 9 | 1 (6%) | 0 (0%) | |
| PSAa, ng/mL | 1.00b | ||
| PSA < 1 ng/mL | 14 (82%) | 9 (82%) | |
| PSA 1 ≤ 2 ng/mL | 0 (0%) | 1 (9%) | |
| PSA ≥ 2 ng/mL | 3 (18%) | 1 (9%) | |
| Interval between PSA prior to F-18 fluciclovineand F-18 fluciclovine scan, days, median (range) | 29 (6, 309) | 13 (0, 68) | .07c |
a
PSA before F-18 fluciclovine scan.b Cells with zero observation were combined with other categories to compute the P-value.c P-value was computed after removing 2 outliers, that is, 149 and 309 days.